Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 7, 2026

Laser Micro-Irradiation to Study DNA Recruitment During S Phase
07:11

Laser Micro-Irradiation to Study DNA Recruitment During S Phase

Published on: April 16, 2021

4.9K

Olaparib.

Sylvia Bochum1, Stephanie Berger2, Uwe M Martens2

  • 1Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH and MOLIT Institute for Personalized Medicine, Am Gesundbrunnen 20-24, 74078, Heilbronn, Germany. sylvia.bochum@molit.eu.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.

Nature cancer·2026
Same author

Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma.

The oncologist·2026
Same author

Stakeholder-Informed Needs Assessment for Open Notes Curriculum in Inpatient Pediatrics.

Academic pediatrics·2026
Same author

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Blood·2026
Same author

Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.

Leukemia·2025
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, targets DNA repair pathways. It shows promise in treating BRCA-mutated ovarian, breast, and prostate cancers by inducing synthetic lethality.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Olaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair.
  • PARP enzymes are crucial for repairing DNA single-strand breaks (SSBs) via the base excision repair (BER) pathway.

Purpose of the Study:

  • To elucidate the mechanism of action of olaparib as a PARP inhibitor.
  • To review the clinical applications and potential of olaparib in cancer treatment.

Main Methods:

  • Olaparib competitively inhibits NAD+ at the catalytic site of PARP1 and PARP2.
  • Inhibition leads to accumulation of unrepaired SSBs and formation of double-strand breaks (DSBs).

Main Results:

  • Olaparib induces synthetic lethality in tumors with homologous recombination repair deficiencies.
Keywords:
ATMBRCADNA repairOlaparibPARP inhibitorSynthetic lethality

Related Experiment Videos

Last Updated: Feb 7, 2026

Laser Micro-Irradiation to Study DNA Recruitment During S Phase
07:11

Laser Micro-Irradiation to Study DNA Recruitment During S Phase

Published on: April 16, 2021

4.9K
  • Approved for BRCA-mutated recurrent ovarian cancer, showing clinical benefits.
  • Demonstrates promising activity in metastatic breast and prostate cancers with germline BRCA mutations.

    • Conclusions:

    • Olaparib is an effective synthetic lethality agent in specific cancer types.
    • Its role as a chemo- and radiosensitizer requires further clinical benefit demonstration.
    • Olaparib represents a significant advancement in targeted cancer therapy.